经腹入路与开放腹主动脉瘤修复术后长期剖腹术相关并发症增加相关
本研究回顾性分析2010-2019年241例开放腹主动脉瘤修复术患者,比较经腹入路(TAA)与侧方入路(LA)后长期剖腹术相关并发症(LCs)。TAA组LCs发生率更高,1、3、5年无LCs生存率显著低于LA组。TAA是LCs的独立预测因素,对于解剖条件合适的患者,LA有利于预防长期LCs。
要点
- TAA组长期LCs发生率显著高于LA组,1、3、5年无LCs生存率分别为77.7%、60.5%、54.0% vs 94.8%、82.2%、79.1%。
- TAA是长期LCs的独立预测因素,其他预测因素包括小肠梗阻病史和体重指数增加。
- 对于解剖条件合适的患者,尤其是高风险患者,LA有利于预防长期LCs。
核心结论
- TAA是开放腹主动脉瘤修复术后长期剖腹术相关并发症的独立预测因素。
- 对于解剖条件合适的患者,LA有利于预防长期LCs,尤其在高风险患者中。
研究设计与样本
- 回顾性队列研究,查询2010-2019年机构开放腹主动脉瘤修复术数据库,排除急诊和紧急病例。
- 共纳入241例患者,平均年龄70.0±9.1岁,71.7%为男性;TAA组91例,LA组150例。
主要发现
- TAA组患者更年轻(66.7±8.9 vs 72.1±8.7岁,P<.001),男性比例更高(83.5% vs 64.7%,P=.002),小肠梗阻病史比例更高(3.3% vs 0%,P=.025)。
- LA组需要腹腔干上阻断的比例更高(20.7% vs 1.1%,P<.001)。
- 最常见的LCs为疝(TAA 26.4% vs LA 11.3%,P=.003)、小肠梗阻(TAA 8.8% vs LA 1.3%,P=.005)和其他(TAA 13.2% vs LA 2.0%,P=.001)。
- 手术相关LCs在TAA组更常见(17.6% vs 2.7%,P<.001)。
- 未调整的1、3、5年无LCs生存率TAA组分别为77.7%(95%CI 66.0%-85.8%)、60.5%(95%CI 46.5%-71.9%)、54.0%(95%CI 38.8%-67.0%),LA组分别为94.8%(95%CI 88.8%-97.7%)、82.2%(95%CI 72.2%-88.9%)、79.1%(95%CI 68.4%-86.5%)(log-rank P<.001)。
关键数值与推荐
- LCs的预测因素包括小肠梗阻病史(P=.001)、体重指数增加(P=.005)和使用TAA(P<.001)。
- 围手术期并发症发生率和长期死亡率两组间无差异。
临床怎么用
- 在开放腹主动脉瘤修复术中,对于解剖条件合适的患者,优先选择侧方入路以降低长期剖腹术相关并发症风险。
- 对于高风险患者(如肥胖、有小肠梗阻病史),应特别考虑避免经腹入路。
局限性
- 回顾性单中心研究,可能存在选择偏倚。
- TAA组和LA组基线特征存在显著差异,如年龄、性别、小肠梗阻病史和阻断位置。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although the transabdominal approach (TAA) and lateral approach (LA) to open abdominal aortic aneurysm repair (OAR) are both acceptable and widely used, a paucity of data evaluating subsequent postoperative laparotomy-associated complications (LCs) is available. The aim of the present study was to establish the incidence of LCs after OAR and determine which approach was associated with an increase in long-term LCs. METHODS: An institutional database for OAR (2010-2019) was queried, excluding urgent and emergent cases. The primary endpoint was long-term LCs, defined as any complication related to entry into the abdomen. The LA included retroperitoneal and thoracoabdominal approaches and the TAA included all patients with midline incisions. A Kaplan-Meier analysis was used to estimate the freedom from LCs, and the Fine-Gray method was used to determine the predictors of LCs, with death as a competing risk. RESULTS: A total of 241 patients (mean age, 70.0 ± 9.1 years; 71.7% men) had undergone OAR, 91 via a TAA and 150 via a LA. The patients in the TAA group were significantly younger (age, 66.7 ± 8.9 vs 72.1 ± 8.7 years; P < .001), more likely to be male (83.5% vs 64.7%; P = .002), and more likely to have a history of small bowel obstruction (SBO; 3.3% vs 0%; P = .025). Patients in the LA group were more likely to have required a supraceliac clamp (20.7% vs 1.1%; P < .001). No difference was found in the incidence of perioperative complications or long-term mortality. The most common LCs were hernia (TAA, 26.4%; LA, 11.3%; P = .003), SBO (TAA, 8.8%, LA, 1.3%; P = .005), and other (TAA, 13.2%; LA, 2.0%; P = .001), which included evisceration, bowel ischemia, splenic injuries requiring reintervention, enterocutaneous fistula, internal hernia, and retrograde ejaculation. Operative LCs were more common in the TAA group (17.6% vs 2.7%; P < .001). The unadjusted 1-, 3-, and 5-year freedom from LCs was 77.7% (95% confidence interval [CI], 66.0%-85.8%), 60.5% (95% CI, 46.5%-71.9%), and 54.0% (95% CI, 38.8%-67.0%) for TAA and 94.8% (95% CI, 88.8%-97.7%), 82.2% (95% CI, 72.2%-88.9%), and 79.1% (95% CI, 68.4%-86.5%) for LA, respectively (log-rank P < .001). The predictors for LCs were a history of SBO (P = .001), increasing body mass index (P = .005), and the use of the TAA (P < .001). CONCLUSIONS: Use of the TAA was an independent predictor of long-term LCs after OAR, along with an increasing body mass index and a history of SBO. In patients with amenable anatomy, the LA is favorable for preventing long-term LCs, especially in high-risk patients.
引用
- DeCarlo C, Manxhari C, Boitano LT, et al. Transabdominal approach associated with increased long-term laparotomy complications after open abdominal aortic aneurysm repair. J Vasc Surg. 2020. PMID: 33080323. doi:10.1016/j.jvs.2020.08.154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。